Chymase Inhibitor as a Novel Therapeutic Agent for Non-alcoholic Steatohepatitis

@inproceedings{Takai2018ChymaseIA,
  title={Chymase Inhibitor as a Novel Therapeutic Agent for Non-alcoholic Steatohepatitis},
  author={Shinji Takai and Denan Jin},
  booktitle={Front. Pharmacol.},
  year={2018}
}
Non-alcoholic steatohepatitis (NASH) is characterized by inflammation and fibrosis, in addition to steatosis, of the liver, but no therapeutic agents have yet been established. The mast cell protease chymase can generate angiotensin II, matrix metalloproteinase-9 and transforming growth factor-β, all of which are associated with liver inflammation or fibrosis. In animal models of NASH, augmented chymase has been observed in the liver. In histological analysis, chymase inhibitor prevented… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
1 Citations
50 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 50 references

Measurement of the internal pH of mast cell granules using microvolumetric fluorescence and isotopic techniques

  • M. B. De Young, E. F. Nemeth, A. Scarpa
  • Arch. Biochem. Biophys
  • 1987
Highly Influential
1 Excerpt

Similar Papers

Loading similar papers…